Mucinex: See Their Revenue, Competitors, Traffic, and Reviews (August 2025)

Review (August 2025)

Fight off your worst symptoms with mucinex® cold and flu medicine. get relief for cough, fever, chest congestion, stuffy nose, sinus pressure, headache and more.

Estimated Revenue

150.05k

Website Visitors

4/5

Trustpilot Score

What do we know about Mucinex?

Total Employees

1-10

About

Mucinex: Fight off your worst symptoms with Mucinex® Cold and Flu Medicine. Get relief for cough, fever, chest congestion, stuffy nose, sinus pressure, headache and more.

Social Links

Alexa Ranking: 264877

What is Mucinex's Revenue?

Mucinex's estimated revenue for 2024 is $0.

What does Mucinex do?

What are the monthly traffic metrics for Mucinex?

6/mo Traffic Growth

4.10%

All Time Traffic Growth

Create Free Account

Monthly Hits

150k

Time on Site

0.6Mins

Bounce Rate

73%

How fast is Mucinex growing?

Mucinex has grown by 2.8% in the last 6 months according to SimilarWeb.

How do people interact with Mucinex?

Last month, Mucinex received 150k visitors who spent an average of 0.6 minutes on the website and visited 1.0 different pages per session. Overall, 73% of people bounce on the first visit.

How do people find Mucinex?

13.6k people (9%) visit Mucinex directly. 132.5k (88%) people search for them in Google. Whereas, 0 (0%) discover Mucinex through Facebook, Reddit, and YouTube. 0 (0%) visitors come from Mucinex's email newsletters. Finally, 2.6k (1.7%) people come from affiliates and or paid referrals.

Who uses Mucinex?

Mucinex's top market is the United States and they receive 138.3k (92.1%) people.
Then the 2nd is United Kingdom with 3.5k (2.3%).
The 3rd is is Mexico with 1.6k (1.1%).

Traffic Growth (last 6 months)

All Traffic Source

Country Share

Traffic Growth (last 12 months)

See 12/mo Traffic Stats

Lattice

Lattice is the people management platform that empowers people leaders to build engaged, high-performing teams, inspire winning cultures, and make strategic, data-driven business decisions.... More